SCHEMBL5147752

SCHEMBL5147752

CC[C@@](Cc1ccc([N+](=O)[O-])cn1)(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.44
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
GAA P10253 2/20 0.38
CYP1A2 P05177 1/20 0.38
MAPT P10636 6/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.36
ALOX5 P09917 1/20 0.35
GSTP1 P09211 1/20 0.35
GSTM2 P28161 1/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3935728 0.83 PPARG (0.49) CYP2C19PPARGPPARACYP1A2MAPT
SCHEMBL3935734 0.83 PPARG (0.49) CYP2C19PPARGPPARACYP1A2MAPT
SCHEMBL5146360 0.83 MAPKAPK2 (0.35)
SCHEMBL5262911 0.83 CTSS (0.35) PPARAGAANPC1RAB9AMEN1
SCHEMBL31455662 0.77 CYP2C19 (0.51) CYP2C19PPARGPPARAGAACYP1A2
SCHEMBL2983425 0.76 PPARA (0.54) CYP2C19PPARGPPARAGSTP1GSTM2
SCHEMBL2983423 0.76 PPARA (0.54) CYP2C19PPARGPPARAGSTP1GSTM2
SCHEMBL27589045 0.76 PPARA (0.54) CYP2C19PPARGPPARAGSTP1GSTM2
SCHEMBL5147742 0.74 PPARG (0.45) CYP2C19PPARGPPARAGAACYP1A2
SCHEMBL5149439 0.73 ITGB1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 CYP2C19 3914/4885PPARG 175/4885PPARA 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.